ClinicalTrials.gg
Active, not recruitingNCT06722664Updated Apr 29, 2025

Efficacy and Safety of OsrhCT and Dimethicone Emulsion Before Upper Endoscopy on Visualization of the Gastric Mucosa.

A Phase 2 interventional study of Recombinant Human Chymotrypsin(OsrhCT) 4000U and Placebo for Recombinant Human Chymotrypsin(OsrhCT) in Gastric Mucosal Lesion, sponsored by Healthgen Biotechnology Corp.. Active, not recruiting at 5 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Healthgen Biotechnology Corp. · Phase 2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
336
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Study was designed to evaluate efficacy of OsrhCT and Dimethicone emulsion before upper endoscopy on visibility of gastric mucosa.

A total of 336 subjects (both male and female) are expected to be enrolled in this trial.

Read the detailed description

This is a monocentric, double-blind, randomized study involving 336 patients indicated for diagnostic upper endoscopy. Patients were randomly assigned to one of three arms, with OsrhCT 4000U+ Dimethicone emulsion 4ml , with OsrhCT 8000U+ Dimethicone emulsion 4ml , and with placebo for OsrhCT+ Dimethicone emulsion 4ml. During the examination, each photograph was individually taken in 5 defined areas. The first 30 cases were collected to establish standards and method validation. The visibility score was given by the sum of the score 1-4 from 5 defined localities evaluated by a blinded endoscopist and subsequently by two or three blinded endoscopists. Other parameters monitored were examination time and a semiquantitative evaluation of residual gastric fluid.

02

Conditions studied

  • Gastric Mucosal Lesion

Keywords

  • OsrhCT
  • Recombinant Human Chymotrypsin
03

In context

Lead sponsor

Healthgen Biotechnology Corp. is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients indicated for gastroscopy examination;
  2. Subjects fully understand the content, process, and possible adverse reactions of the trial and voluntary participation with signed ;
  3. Able to complete the research according to the requirements of the experimental plan;
  4. Subjects (including their spouses) voluntarily have no pregnancy plans and use during the study and within 3 months after the last administration of the study drug;
  5. Aged 18-75 years (inclusive), male or female;

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to chymotrypsin; Known to be allergic to preparation or anesthesia medication before gastroscopy examination;
  2. Patients plan to undergo gastroscopic treatment, such as endoscopic titanium clip for hemostasis, esophagogastric fundal variceal ligation, endoscopic mucosal stripping, etc;
  3. Subjects accessed not to stand sedation anesthesia or gastroscopy examination;
  4. Severe cardiovascular, pulmonary, or cerebral diseases, such as angina, heart failure, and new-onset stroke; or severe liver disease, cirrhosis, or esophagogastric fundus varices;
  5. Suspected or known esophageal fistula, tracheal fistula, intestinal obstruction, active gastrointestinal bleeding, gastric perforation, history of anatomically altered upper GI surgery;
  6. Abnormal laboratory values:: (ALT)>2 × , aspartate aminotransferase (AST)>2 × ULN, serum creatinine>1.5 × ULN;
  7. Female subjects who had unprotected sex within 14 days prior to screening;
  8. Pregnant or breastfeeding women;
  9. Subjects who have participated in any drug clinical trial and received treatment within the last 3 months;
  10. Any other conditions deemed unsuitable for the study by the investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
336 participants (estimated)

Study arms

  • Experimental
    Recombinant Human Chymotrypsin(OsrhCT) 4000U

    Drug: Recombinant Human Chymotrypsin(OsrhCT) 4000U · Drug: Placebo for Recombinant Human Chymotrypsin(OsrhCT) · Drug: Dimethicone emulsion 4ml

  • Experimental
    Recombinant Human Chymotrypsin(OsrhCT) 8000U

    Drug: Recombinant Human Chymotrypsin(OsrhCT) 4000U · Drug: Dimethicone emulsion 4ml

  • Placebo comparator
    Placebo for Recombinant Human Chymotrypsin(OsrhCT)

    Drug: Placebo for Recombinant Human Chymotrypsin(OsrhCT) · Drug: Dimethicone emulsion 4ml

Interventions

  • DrugRecombinant Human Chymotrypsin(OsrhCT) 4000U

    Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder

  • DrugPlacebo for Recombinant Human Chymotrypsin(OsrhCT)

    Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 0 U/vial, freeze-dried powder

  • DrugDimethicone emulsion 4ml

    Dimethicone emulsion,produced by Sichuan Jian Neng Pharmaceutical Co., Ltd, 6ml/bottle.

06

What researchers measure

Primary outcomes

  1. Total visibility score (TVS) evaluated by blinded endoscopists

    "Total visibility score"counted as the sum of visibility score in lower esophagus, gastric fundus, upper gastric body, lower gastric body and gastric antrum.

    Time frame: Through study completion, an average of 3 months

Secondary outcomes

  1. Vsibility scores evaluated by blinded endoscopists for mucosain of 5 various anatomical parts of the stomach

    Vsibility scores for the lower esophagus, antrum, lower gastric body, upper gastric body, and fundus.

    Time frame: Through study completion, an average of 3 months

  2. The amount of water flushed for satisfactory observation of the upper gastrointestinal tract

    Amount of water used to allow an suitable visualization of gastric mucosa

    Time frame: during diagnostic upper endoscopy, up to 1 hour

  3. Duration of endoscopy

    Time to complete the upper endoscopy (from the time of oral intubation until complete removal of the endoscope)

    Time frame: during diagnostic upper endoscopy, up to 1 hour

  4. Incidence of adverse events

    Number of gastroscopy procedures with adverse event divided by the number of all gastroscopy procedures. Number of participants with treatment-related adverse events as assessed by CTCAE V5.0.

    Time frame: up to 1 week

Other outcomes

  1. Establishment and method validation of the criteria for mucosal visibility score

    The first 30 cases were collected to establish standards and method validation. The visibility score was given by the sum of the score 1-4 from 5 defined localities (lower esophagus, gastric fundus, upper gastric body, lower gastric body and gastric antrum) evaluated by a blinded endoscopist and subsequently by two or three blinded endoscopists.

    Time frame: Through study completion, an average of 3 months

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for May 2025, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2024
First posted
Dec 9, 2024
StartActual
Dec 19, 2024
Primary completionEst.
May 15, 2025
CompletionEst.
May 15, 2025
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06722664
Lead sponsor
Healthgen Biotechnology Corp.
Responsible party
Sponsor
First posted
Dec 9, 2024
Start date
Dec 19, 2024
Primary completion
May 15, 2025 (estimated)
Completion
May 15, 2025 (estimated)
Last update
Apr 29, 2025

Study contacts

Shutian Zhang, MD
principal investigator · Beijing Friendship Hospital
Fandong Meng, MD
principal investigator · Beijing Friendship Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion